Literature DB >> 2611086

Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.

Q Y Yue1, J O Svensson, C Alm, F Sjöqvist, J Säwe.   

Abstract

1. A single oral dose of codeine (25 mg) was given to 132 healthy Swedish Caucasians who had previously been phenotyped with respect to debrisoquine hydroxylation. The 'metabolic ratios' (MR) in urine of codeine O-demethylation (codeine/(morphine (M) + morphine-3- and 6-glucuronides (M3G and M6G) + normorphine], N-demethylation (codeine/(norcodeine (NC) + norcodeine glucuronide + normorphine (NM]) and glucuronidation (codeine/codeine-6-glucuronide (C6G] were calculated following h.p.l.c. analysis of urine samples collected over 8 h. 2. There was a significant correlation between the log MR for debrisoquine hydroxylation and the log MR for codeine O-demethylation (rs = 0.77, P less than 0.001). The poor debrisoquine hydroxylators had MRs of codeine O-demethylation between 8.3 and 55.1, while the values for extensive hydroxylators were between 0.4 and 5.5. 3. The poor debrisoquine hydroxylators excreted significantly less M, M3G, M6G and NM, while the urinary recovery of C6G and NC was significantly higher in these subjects compared to the extensive hydroxylators. 4. The MRs for glucuronidation and N-demethylation did not exhibit a bimodal distribution, and were not related to the MR of debrisoquine hydroxylation. 5. No associations were found between sex, body-weight, smoking habits, age, urine volume or urine pH and the O-demethylation of codeine. 6. The O-demethylation of codeine to form M appears to be under the same polymorphic genetic control as the 4-hydroxylation of debrisoquine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611086      PMCID: PMC1380034          DOI: 10.1111/j.1365-2125.1989.tb03556.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Analgesic potency of normorphine in patients with postoperative pain.

Authors:  L LASAGNA; T J DE KORNFELD
Journal:  J Pharmacol Exp Ther       Date:  1958-11       Impact factor: 4.030

2.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

3.  Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.

Authors:  J O Svensson; A Rane; J Säwe; F Sjöqvist
Journal:  J Chromatogr       Date:  1982-07-09

4.  Tolerance and side effects during long term treatment of hypertension with debrisoquine.

Authors:  W B Jackson
Journal:  Aust N Z J Med       Date:  1972-11

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

Review 6.  Human cytochromes P-450.

Authors:  A R Boobis; D S Davies
Journal:  Xenobiotica       Date:  1984 Jan-Feb       Impact factor: 1.908

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Codeine disposition in smokers and nonsmokers.

Authors:  J F Rogers; J W Findlay; J H Hull; R F Butz; E C Jones; J A Bustrack; R M Welch
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

9.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  33 in total

Review 1.  Drug interactions and the statins.

Authors:  R J Herman
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

2.  Perturbation of paracetamol urinary metabolic ratios by urine flow rate.

Authors:  J O Miners; N J Osborne; A L Tonkin; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 3.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

4.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

5.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.

Authors:  I Johansson; Q Y Yue; M L Dahl; M Heim; J Säwe; L Bertilsson; U A Meyer; F Sjöqvist; M Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man.

Authors:  A Somogyi; F Bochner; Z R Chen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration.

Authors:  H Quiding; G L Olsson; L O Boreus; U Bondesson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

8.  Impact of environmental and genetic factors on codeine analgesia.

Authors:  J Desmeules; M P Gascon; P Dayer; M Magistris
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.

Authors:  Hadi Molanaei; Juan Jesus Carrero; Olof Heimbürger; Louise Nordfors; Bengt Lindholm; Peter Stenvinkel; Ingegerd Odar-Cederlöf; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2009-11-26       Impact factor: 2.953

10.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.